Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib maintenance in stage III/IV NSCLC
NCT01210053Phase 2Unknown
- Sponsor
- Army Medical University
- Start
- Sep 2010
- Primary completion
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sunitinib in non-small cell lung cancer (NSCLC), sponsored by Army Medical University. Primary endpoint: Progression-Free Survival at 2 years. Status: unknown.
02
Drugs
sunitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01210053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01210053.